--- a
+++ b/clusters/9knumclustersv2/clust_1541.txt
@@ -0,0 +1,29 @@
+U.S. ONLY: For all Cohorts, patients who refuse approved therapy for which they are a suitable candidate are not eligible for enrollment on this trial.
+Subjects must refuse or be deemed ineligible for cisplatin-based chemotherapy.
+Subject must refuse or not be eligible for radiotherapy.
+Not a candidate for or refuse chemotherapy
+Patients must have had at least one prior therapy to be eligible for either phase I or II, unless they are either not candidates for or refuse cisplatin-based therapy
+Patients who refuse to receive blood transfusions
+For clinically stage II patients, the patient must have been evaluated by a thoracic surgeon, and deemed medically or technically inoperable, or the patient must refuse surgery
+Patients who refuse standard therapy are excluded from the study
+Subjects must refuse cisplatin-based combination chemotherapy (and understand the risk and benefits of doing so) or be deemed ineligible for cisplatin-based chemotherapy by meeting at least one of the following criteria:
+Women who are pregnant or lactating or refuse to commit to use contraception anytime during the study
+Patients of fertile age who refuse contraception for a twelve month period post-transplant
+Dose Expansion: Patients with relapsed AML or patients who refuse, or are not suitable candidates for induction therapy
+Previously untreated RT patients deemed ineligible for, or that refuse, intensive chemotherapy are eligible.
+Refuse of use of contraception during trial (both male and female patients)
+Patients who may have high burden of disease ie large lesions, who are non-surgical candidates or who refuse surgery
+Subjects who refuse blood products.
+Patients who are not surgical candidates or refuse surgery
+patients who refuse additional radiation therapy.
+Patients who refuse to participate
+Subjects medically eligible for neoadjuvant cisplatin-based combination chemotherapy who refuse this therapeutic option and understand the risks and benefits of doing so.
+Patients with pTa disease who lack one of the above criteria, and who refuse adjuvant radiation, may also be enrolled
+Patients who refuse to participate
+Subjects who refuse to participate, or demonstrate inability to give informed consent
+Subjects who refuse to give and/or sign the informed consent
+Patients who are not surgical candidates or refuse to undergo surgery and choose any percutaneous ablation as an alternative treatment option
+Subjects who refuse to participate, or demonstrate inability to give informed consent
+Patients who refuse to participate
+Patients who refuse to participate
+Patients who refuse to participate in the study